2019
Future epidemiological and economic impacts of universal influenza vaccines
Sah P, Alfaro-Murillo JA, Fitzpatrick MC, Neuzil KM, Meyers LA, Singer BH, Galvani AP. Future epidemiological and economic impacts of universal influenza vaccines. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 20786-20792. PMID: 31548402, PMCID: PMC6789917, DOI: 10.1073/pnas.1909613116.Peer-Reviewed Original ResearchConceptsUniversal influenza vaccineDirect health care costsInfluenza vaccineSeasonal vaccineUniversal vaccineHealth care costsCare costsInfluenza-related deathsVaccines actVaccine mismatchRapid antigenic evolutionInfluenza transmissionVaccine developmentVaccineInfectious diseasesPopulation-level impactElderly residentsMedical expensesNational InstituteHospitalizationAntigenic evolutionDeathEfficacyLarge proportionAllergy
2016
A Cost-Effectiveness Tool for Informing Policies on Zika Virus Control
Alfaro-Murillo JA, Parpia AS, Fitzpatrick MC, Tamagnan JA, Medlock J, Ndeffo-Mbah ML, Fish D, Ávila-Agüero ML, Marín R, Ko AI, Galvani AP. A Cost-Effectiveness Tool for Informing Policies on Zika Virus Control. PLOS Neglected Tropical Diseases 2016, 10: e0004743. PMID: 27205899, PMCID: PMC4874682, DOI: 10.1371/journal.pntd.0004743.Peer-Reviewed Original ResearchConceptsGuillain-Barré syndromeZika infectionHealth burdenVirus controlRisk of microcephalyDirect medical costsCost-effectiveness toolsCurrent Zika outbreakGBS casesMedical costsZika casesZika virusMicrocephalyIncidence dataCountry of implementationZika outbreakInfectionInterventionBurdenInforming PolicyDALYsCountry-specific settingsOutbreakMosquitoesPregnancy
2015
Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US
Alfaro-Murillo JA, Townsend JP, Galvani AP. Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US. Vaccine 2015, 34: 225-229. PMID: 26631416, DOI: 10.1016/j.vaccine.2015.11.039.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolCytomegalovirus InfectionsCytomegalovirus VaccinesDisease Transmission, InfectiousFemaleHumansImmunization ScheduleInfantInfant, NewbornInfectious Disease Transmission, VerticalMaleMass ScreeningMiddle AgedUnited StatesYoung AdultConceptsVaccine waningVaccine efficacyOptimal ageCMV vaccine candidatesLongitudinal clinical evaluationChild-bearing yearsYears of ageTransmission dynamicsCMV prevalenceCMV vaccinationCytomegalovirus ScreeningSeronegative femalesCongenital infectionCytomegalovirus infectionVaccine protectionSuch vaccinationClinical evaluationClinical trialsHearing lossVaccine candidatesVaccinationDemographic dataCongenital diseaseCognitive deficitsIndirect protection